J&J Agrees to $5.5 Billion Settlement to End Decade of Talc Cancer Lawsuits
Johnson & Johnson agrees to pay $5.5 billion to settle ~76,000 lawsuits claiming its talc baby powder caused ovarian cancer, ending 10+ years of litigation.
/ 352 items
#XY Event-Driven Stocks↓
Legend Biotech CEO Abruptly Resigns Without Permanent Successor
Legend Biotech CEO Ying Huang steps down. Carvykti president Alan Bash named interim CEO while search for permanent successor continues.
Morgan Stanley on Sarepta’s CEO Switch: Clear Handover Is Positive, but DMD Challenges Linger
Michael Severino becomes Sarepta’s new CEO as Doug Ingram retires.
Capricor Shares Plunge After FDA Briefing Documents Raise Doubts on Deramiocel
FDA briefing documents for Capricor’s deramiocel question effectiveness and highlight safety risks ahead of the July 29 advisory committee.
H.C. Wainwright Reiterates Buy on Omeros After AstraZeneca’s Ultomiris Phase 3 Miss
AstraZeneca’s Ultomiris Phase 3 miss in adult HSCT-TMA is a clear positive for Omeros’ Yartemlea, removing a key rival.
Positive ZEPHYR Trial Results Fail to Impress Investors as MapLight Stock Plunges
MapLight ZEPHYR trial: BID dose hits primary endpoint & cognitive goals, but QD misses; shares plunge over 60% on mixed schizophrenia data.